Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

达帕格列嗪 医学 肾功能 肾脏疾病 2型糖尿病 内科学 泌尿科 糖尿病 重症监护医学 内分泌学
作者
Hiddo J.L. Heerspink,Niels Jongs,Glenn Matthew Chertow,Anna Maria Langkilde,John J.V. McMurray,Ricardo Correa‐Rotter,Peter R Rossing,C. David Sjöström,Bergur V. Stefánsson,Robert D. Toto,David Collins. Wheeler,Tom Greene
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (11): 743-754 被引量:247
标识
DOI:10.1016/s2213-8587(21)00242-4
摘要

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)—ie, the eGFR slope. Methods DAPA-CKD was a randomised controlled trial that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatinine ratio (UACR) of 200–5000 mg/g, and an eGFR of 25–75 mL/min per 1·73m 2 . Participants were randomly assigned (1:1) to oral dapagliflozin 10 mg once daily or placebo, added to standard care. In this pre-specified analysis, we analysed eGFR slope using mixed-effect models with different slopes from baseline to week 2 (acute eGFR decline), week 2 to end of treatment (chronic eGFR slope), and baseline to end of treatment (total eGFR slope). DAPA-CKD is registered with ClinicalTrials.gov, NCT03036150, and is now complete. Findings Between Feb 2, 2017, and April 3, 2020, 4304 participants were recruited, of whom 2152 (50%) were assigned to dapagliflozin and 2152 (50%) were assigned to placebo. At baseline, the mean age was 62 years (SD 12), 1425 (33·1%) participants were women, 2906 (67·5%) participants had type 2 diabetes. The median on-treatment follow-up was 2·3 years (IQR 1·8–2·6). From baseline to the end of treatment, dapagliflozin compared with placebo slowed eGFR decline by 0·95 mL/min per 1·73 m 2 per year (95% CI 0·63 to 1·27) in the overall cohort. Between baseline and week 2, dapagliflozin compared with placebo resulted in an acute eGFR decline of 2·61 mL/min per 1·73 m 2 (2·16 to 3·06) in patients with type 2 diabetes and 2·01 mL/min per 1·73 m 2 (1·36 to 2·66) in those without type 2 diabetes. Between week 2 and end of treatment, dapagliflozin compared with placebo reduced the mean rate of eGFR decline by a greater amount in patients with type 2 diabetes (mean difference in chronic eGFR slope 2·26 mL/min per 1·73 m 2 per year [1·88 to 2·64]) than in those without type 2 diabetes (1·29 mL/min per 1·73 m 2 per year [0·73 to 1·85]; p interaction =0·0049). Between baseline and end of treatment, the effect of dapagliflozin compared with placebo on the decline of total eGFR slope in patients with type 2 diabetes was 1·18 mL/min per 1·73 m 2 per year (0·79 to 1·56) and without type 2 diabetes was 0·46 mL/min per 1·73 m 2 per year (–0·10 to 1·03; p interaction =0·040). The total eGFR slope was steeper in patients with higher baseline HbA 1c and UACR; the effect of dapagliflozin on eGFR slope was also more pronounced in patients with higher baseline HbA 1c and UACR. Interpretation Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney disease compared with placebo. The mean difference in eGFR slope between patients treated with dapagliflozin versus placebo was greater in patients with type 2 diabetes, higher HbA 1c , and higher UACR. Funding AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
jokery完成签到,获得积分10
刚刚
刚刚
1秒前
2秒前
biancaliu完成签到,获得积分10
2秒前
小二郎的应助被koopa采纳,获得10
3秒前
王小花发布了新的文献求助10
4秒前
李68发布了新的文献求助10
4秒前
4秒前
huang完成签到,获得积分10
4秒前
苗子发布了新的文献求助20
4秒前
WANG的应助被踏实的酸奶采纳,获得10
4秒前
孤独的觅山完成签到,获得积分10
4秒前
Zhupegnju发布了新的文献求助10
5秒前
xinbadake发布了新的文献求助50
5秒前
5秒前
5秒前
月月月月发布了新的文献求助200
6秒前
魔幻冬寒发布了新的文献求助10
6秒前
6秒前
cc完成签到,获得积分10
6秒前
Owen的应助被CJY采纳,获得10
6秒前
小汤圆发布了新的文献求助10
6秒前
段佳佳发布了新的文献求助10
6秒前
8秒前
Anonymous的应助被简单若风采纳,获得20
8秒前
8秒前
王D完成签到,获得积分10
8秒前
8秒前
传奇3的应助被Lucky采纳,获得10
8秒前
辣条完成签到,获得积分20
9秒前
9秒前
天天快乐的应助被chenghuan采纳,获得10
9秒前
共享精神的应助被研友_8yrPOL采纳,获得10
10秒前
10秒前
yanzi发布了新的文献求助10
10秒前
chaser发布了新的文献求助10
10秒前
charon关注了科研通微信公众号
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182706
求助须知:如何正确求助?哪些是违规求助? 9572086
关于积分的说明 21822405
捐赠科研通 7779207
什么是DOI,文献DOI怎么找? 3433702
关于科研通互助平台的介绍 2557891
邀请新用户注册赠送积分活动 2479787